Bhargava, P.
2201  results:
Search for persons X
?
 
?
3

Randomized phase III clinical trial:Non-inferiority of redu..:

Kumar, A. ; Ostwal, V. ; Bhargava, P....
Journal of Geriatric Oncology.  14 (2023)  8 - p. S1-S2 , 2023
 
?
4

PO-1282 Local control still a challenge in post-SBRT advanc..:

Krishnatry, R. ; Anup, A. ; Ramaswamy, A....
Radiotherapy and Oncology.  170 (2022)  - p. S1080-S1081 , 2022
 
?
6

Contribution of higher modes in the dynamic response of rei..:

Bhatt, Anita ; Bhargava, P ; Maheshwari, P
IOP Conference Series: Earth and Environmental Science.  871 (2021)  1 - p. 012003 , 2021
 
?
7

Impact of baseline factors on response to apomorphine subli..:

Nicholas, A. ; Singer, C. ; Robottom, B...
Parkinsonism & Related Disorders.  79 (2020)  - p. e85 , 2020
 
?
8

Patient-reported motor responses to apomorphine sublingual ..:

Hauser, R. ; Mehta, S. ; Maulis, M....
Parkinsonism & Related Disorders.  79 (2020)  - p. e74-e75 , 2020
 
?
9

PSA Level-3 Study—Estimation of Area and Persons Affected f..:

, In: Reliability, Safety and Hazard Assessment for Risk-Based Technologies; Lecture Notes in Mechanical Engineering,
Bhargava, P. ; Kumar, Praveen ; Kumar, Brij... - p. 51-58 , 2019
 
?
10

TREATMENT EMERGENT ADVERSE EVENTS VARY WITH DIFFERENT PI3K ..:

Awan, F.T. ; Chan, R.J. ; Gu, L....
Hematological Oncology.  37 (2019)  S2 - p. 523-524 , 2019
 
?
11

IDELALISIB PLUS ANTI‐CD20 USED SECOND LINE SHOWS IMPROVED P..:

Brown, J.R. ; Chan, R.J. ; Xing, G....
Hematological Oncology.  37 (2019)  S2 - p. 385-386 , 2019
 
1-15